(Journal Article): Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation.
 
Asano M, Toda M, Sakaguchi N, Sakaguchi S (Department of Immunopathology, Tokyo Metropolitan Institute of Geromology, Japan)
 
IN: J Exp Med 1996; 184(27):387-396
Impact Factor(s) of J Exp Med: 14.588 (2004), 15.302 (2003), 15.34 (2001)

Fulltext:    HTML  PDF

ABSTRACT: Neonatal thymectomy (NTx), especially around day 3 after birth, causes various organ-specific autoimmune diseases in mice. This report shows that: (a) T cells expressing the interleukin 2 receptor alpha chains (CD25) ontogenically begin to appear in the normal periphery immediately after day 3, rapidly increasing within 2 wk to nearly adult levels (approximately 10% of CD3+ cells, especially of CD4+ cells); (b) NTx on day 3 eliminates CD25+ T cells from the periphery for several days; inoculation immediately after NTx of CD25+ splenic T cells from syngeneic non-Tx adult mice prevents autoimmune development, whereas inoculation of CD25- T cells even at a larger dose does not; and furthermore, (c) similar autoimmune diseases can be produced in adult athymic nu/nu mice by inoculating either spleen cell suspensions from 3-d-old euthymic nu/+ mice or CD25+ cell-depleted spleen cell suspensions from older, even 1-yr-old, nu/+ mice. The CD25- populations from neonates or adults are also similar in the profile of cytokine formation. These results, taken together, indicate that one aspect of peripheral self-tolerance is maintained by CD25+ T cells that sustain potentially pathogenic self-reactive T cells in a CD25- dormant state; the thymic production of the former is developmentally programmed to begin on day 3 after birth in mice. Thus, NTx on day 3 can, at least transiently, eliminate/reduce the autoimmune-preventive CD25+ T cells, thereby leading to activation of the self-reactive T cells that have been produced before NTx.

TYPE OF PUBLICATION: Original article

Articles citing this article:

• Thomas D, Zaccone P, Cooke A. The Role of Regulatory T Cell Defects in Type I Diabetes and the Potential of these Cells for Therapy. Rev Diabetic Stud 2005. 2: 9-18.
  » Diabetes OD » Reversal/Prevention of Diabete... » T1DM » Re-establishing Tolerance » Modifying Immunity » Journal Article